<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7905840</journal-id>
<journal-id journal-id-type="pubmed-jr-id">6445</journal-id>
<journal-id journal-id-type="nlm-ta">Pharmacol Ther</journal-id>
<journal-id journal-id-type="iso-abbrev">Pharmacol. Ther.</journal-id>
<journal-title-group>
<journal-title>Pharmacology &amp; therapeutics</journal-title>
</journal-title-group>
<issn pub-type="ppub">0163-7258</issn>
<issn pub-type="epub">1879-016X</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29262295</article-id>
<article-id pub-id-type="pmc">5899024</article-id>
<article-id pub-id-type="doi">10.1016/j.pharmthera.2017.12.004</article-id>
<article-id pub-id-type="manuscript">NIHMS928556</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Potential for Therapeutic Targeting of AKAP Signaling Complexes in Nervous System Disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wild</surname>
<given-names>Angela R.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dell’Acqua</surname>
<given-names>Mark L.</given-names>
</name>
</contrib>
<aff id="A1">Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO, USA, 80045</aff>
</contrib-group>
<author-notes>
<corresp id="FN1">Correspondence: Mark L. Dell’Acqua, Department of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, 12800 E. 19<sup>th</sup> Ave., Aurora, CO, USA, 80045, Phone 303-724-3616; fax 303-724-3663, <email>mark.dellacqua@ucdenver.edu</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p>
<bold>11. <underline>Conflict of interest statement</underline></bold>
</p>
<p>The authors declare that there are no conflicts of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>18</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>17</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>5</month>
<year>2019</year>
</pub-date>
<volume>185</volume>
<fpage>99</fpage>
<lpage>121</lpage>
<!--elocation-id from pubmed: 10.1016/j.pharmthera.2017.12.004-->
<abstract>
<p id="P2">A common feature of neurological and neuropsychiatric disorders is a breakdown in the integrity of intracellular signal transduction pathways. Dysregulation of ion channels and receptors in the cell membrane and the enzymatic mediators that link them to intracellular effectors can lead to synaptic dysfunction and neuronal death. However, therapeutic targeting of these ubiquitous signaling elements can lead to off-target side effects due to their widespread expression in multiple systems of the body. A-kinase anchoring proteins (AKAPs) are multivalent scaffolding proteins that compartmentalize a diverse range of receptor and effector proteins to streamline signaling within nanodomain signalosomes. A number of essential neurological processes are known to critically depend on AKAP-directed signaling and an understanding of the role AKAPs play in nervous system disorders has emerged in recent years. Selective targeting of AKAP protein-protein interactions may be a means to uncouple pathologically active signaling pathways in neurological disorders with a greater degree of specificity. In this review we will discuss the role of AKAPs in both regulating normal nervous system function and dysfunction associated with disease, and the potential for therapeutic targeting of AKAP signaling complexes.</p>
</abstract>
<kwd-group>
<kwd>AKAP</kwd>
<kwd>Calcium</kwd>
<kwd>cAMP</kwd>
<kwd>Ion channel</kwd>
<kwd>Nervous system</kwd>
<kwd>PKA</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>